218 related articles for article (PubMed ID: 24731238)
1. Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections.
Li Q; O'Neil M; Xie L; Caridha D; Zeng Q; Zhang J; Pybus B; Hickman M; Melendez V
Malar J; 2014 Apr; 13():141. PubMed ID: 24731238
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.
Milner EE; Berman J; Caridha D; Dickson SP; Hickman M; Lee PJ; Marcsisin SR; Read LT; Roncal N; Vesely BA; Xie LH; Zhang J; Zhang P; Li Q
Malar J; 2016 Dec; 15(1):588. PubMed ID: 27923405
[TBL] [Abstract][Full Text] [Related]
3. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
St Jean PL; Xue Z; Carter N; Koh GC; Duparc S; Taylor M; Beaumont C; Llanos-Cuentas A; Rueangweerayut R; Krudsood S; Green JA; Rubio JP
Malar J; 2016 Feb; 15():97. PubMed ID: 26888075
[TBL] [Abstract][Full Text] [Related]
4. Causal prophylactic efficacy of primaquine, tafenoquine, and atovaquone-proguanil against Plasmodium cynomolgi in a rhesus monkey model.
DiTusa C; Kozar MP; Pybus B; Sousa J; Berman J; Gettayacamin M; Im-erbsin R; Tungtaeng A; Ohrt C
J Parasitol; 2014 Oct; 100(5):671-3. PubMed ID: 24780070
[TBL] [Abstract][Full Text] [Related]
5. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.
Marcsisin SR; Sousa JC; Reichard GA; Caridha D; Zeng Q; Roncal N; McNulty R; Careagabarja J; Sciotti RJ; Bennett JW; Zottig VE; Deye G; Li Q; Read L; Hickman M; Dhammika Nanayakkara NP; Walker LA; Smith B; Melendez V; Pybus BS
Malar J; 2014 Jan; 13():2. PubMed ID: 24386891
[TBL] [Abstract][Full Text] [Related]
6. Tafenoquine for the prophylaxis, treatment and elimination of malaria: eagerness must meet prudence.
Val F; Costa FT; King L; Brito-Sousa JD; Bassat Q; Monteiro WM; Siqueira AM; Luzzatto L; Lacerda MV
Future Microbiol; 2019 Oct; 14():1261-1279. PubMed ID: 31596137
[TBL] [Abstract][Full Text] [Related]
7. Scalable preparation and differential pharmacologic and toxicologic profiles of primaquine enantiomers.
Nanayakkara NP; Tekwani BL; Herath HM; Sahu R; Gettayacamin M; Tungtaeng A; van Gessel Y; Baresel P; Wickham KS; Bartlett MS; Fronczek FR; Melendez V; Ohrt C; Reichard GA; McChesney JD; Rochford R; Walker LA
Antimicrob Agents Chemother; 2014 Aug; 58(8):4737-44. PubMed ID: 24913163
[TBL] [Abstract][Full Text] [Related]
8. 4(1H)-Quinolones with liver stage activity against Plasmodium berghei.
Lacrue AN; Sáenz FE; Cross RM; Udenze KO; Monastyrskyi A; Stein S; Mutka TS; Manetsch R; Kyle DE
Antimicrob Agents Chemother; 2013 Jan; 57(1):417-24. PubMed ID: 23129047
[TBL] [Abstract][Full Text] [Related]
9. Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
Warrasak S; Euswas A; Fukuda MM; Ittiverakul M; Miller RS; Krudsood S; Ohrt C
Int Ophthalmol; 2019 Aug; 39(8):1767-1782. PubMed ID: 30269312
[TBL] [Abstract][Full Text] [Related]
10. The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines.
Peters W; Stewart LB; Robinson BL
Ann Trop Med Parasitol; 2003 Apr; 97(3):221-36. PubMed ID: 12803854
[TBL] [Abstract][Full Text] [Related]
11. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6.
Pybus BS; Marcsisin SR; Jin X; Deye G; Sousa JC; Li Q; Caridha D; Zeng Q; Reichard GA; Ockenhouse C; Bennett J; Walker LA; Ohrt C; Melendez V
Malar J; 2013 Jun; 12():212. PubMed ID: 23782898
[TBL] [Abstract][Full Text] [Related]
12. Liver-targeted polymeric prodrugs of 8-aminoquinolines for malaria radical cure.
Srinivasan S; Roy D; Chavas TEJ; Vlaskin V; Ho DK; Pottenger A; LeGuyader CLM; Maktabi M; Strauch P; Jackson C; Flaherty SM; Lin H; Zhang J; Pybus B; Li Q; Huber HE; Burke PA; Wesche D; Rochford R; Stayton PS
J Control Release; 2021 Mar; 331():213-227. PubMed ID: 33378692
[TBL] [Abstract][Full Text] [Related]
13. Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice.
Melariri P; Kalombo L; Nkuna P; Dube A; Hayeshi R; Ogutu B; Gibhard L; deKock C; Smith P; Wiesner L; Swai H
Int J Nanomedicine; 2015; 10():1493-503. PubMed ID: 25759576
[TBL] [Abstract][Full Text] [Related]
14. KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro.
Zeeman AM; van Amsterdam SM; McNamara CW; Voorberg-van der Wel A; Klooster EJ; van den Berg A; Remarque EJ; Plouffe DM; van Gemert GJ; Luty A; Sauerwein R; Gagaring K; Borboa R; Chen Z; Kuhen K; Glynne RJ; Chatterjee AK; Nagle A; Roland J; Winzeler EA; Leroy D; Campo B; Diagana TT; Yeung BK; Thomas AW; Kocken CH
Antimicrob Agents Chemother; 2014; 58(3):1586-95. PubMed ID: 24366744
[TBL] [Abstract][Full Text] [Related]
15. Primaquine-thiazolidinones block malaria transmission and development of the liver exoerythrocytic forms.
Aguiar AC; Figueiredo FJ; Neuenfeldt PD; Katsuragawa TH; Drawanz BB; Cunico W; Sinnis P; Zavala F; Krettli AU
Malar J; 2017 Mar; 16(1):110. PubMed ID: 28279180
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta).
Saunders D; Vanachayangkul P; Imerbsin R; Khemawoot P; Siripokasupkul R; Tekwani BL; Sampath A; Nanayakkara NP; Ohrt C; Lanteri C; Gettyacamin M; Teja-Isavadharm P; Walker L
Antimicrob Agents Chemother; 2014 Dec; 58(12):7283-91. PubMed ID: 25267666
[TBL] [Abstract][Full Text] [Related]
17. Preparation, characterization, and optimization of primaquine-loaded solid lipid nanoparticles.
Omwoyo WN; Ogutu B; Oloo F; Swai H; Kalombo L; Melariri P; Mahanga GM; Gathirwa JW
Int J Nanomedicine; 2014; 9():3865-74. PubMed ID: 25143734
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility of tafenoquine vs. primaquine for the radical cure (prevention of relapse) of
Kostić M; Milosavljević MN; Stefanović S; Ranković G; Janković SM
J Chemother; 2020 Feb; 32(1):21-29. PubMed ID: 31524099
[TBL] [Abstract][Full Text] [Related]
19. The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605.
Peters W; Robinson BL; Milhous WK
Ann Trop Med Parasitol; 1993 Dec; 87(6):547-52. PubMed ID: 8122915
[TBL] [Abstract][Full Text] [Related]
20. Application of the Stable Isotope Label Approach in Clinical Development-Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound.
Goyal N; Mohamed K; Rolfe K; Sahota S; Ernest T; Duparc S; Taylor M; Casillas L; Koh GCKW
AAPS J; 2018 Jun; 20(4):74. PubMed ID: 29869298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
